• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Diversity in MHC class II ovalbumin T cell epitopes generated by distinct proteases.

作者信息

Vidard L, Rock K L, Benacerraf B

机构信息

Dana-Farber Cancer Institute, Division of Lymphocyte Biology, Boston, MA 02115.

出版信息

J Immunol. 1992 Jul 15;149(2):498-504.

PMID:1378066
Abstract

It is generally accepted that a limited number of T cell epitopes are generated by APC from an immunogenic protein. To ascertain the number of determinants on OVA recognized in the context of the H-2s haplotype, we generated 19 T-T hybridomas against OVA and H-2s and we synthesized 46 overlapping peptides spanning the entire protein. Eighteen T-T hybrids were stimulated by eight different peptides. The peptide recognized by one T cell hybrid was not identified. The effect of four protease inhibitors on the processing and presentation of OVA by the LS.102.9 B cell hybridoma seemed to implicate several groups of proteases in the processing of this Ag. Alkylation of cysteine residues with iodoacetic acid showed in a few cases a dramatic decrease in the capacity of OVA to stimulate T-T hybrids recognizing cysteine-free peptides. In contrast, two T-T hybrids recognizing cysteine containing peptides were not affected by the alkylation, suggesting that alkylation inhibited the processing of OVA without affecting peptide interaction with class II MHC molecules. These data demonstrate that the repertoire of peptides generated by APC from OVA is not limited to one or few immunodominant peptides, and results from the activity of several endopeptidases and/or exopeptidases. In addition, the structure of the Ag (native or denatured) was shown to affect the efficiency with which different epitopes are generated.

摘要

相似文献

1
Diversity in MHC class II ovalbumin T cell epitopes generated by distinct proteases.
J Immunol. 1992 Jul 15;149(2):498-504.
2
Different roles for thiol and aspartyl proteases in antigen presentation of ovalbumin.巯基蛋白酶和天冬氨酰蛋白酶在卵清蛋白抗原呈递中的不同作用。
J Immunol. 1990 Jul 15;145(2):417-22.
3
The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors.免疫原性肽的产生可通过蛋白水解酶抑制剂选择性地增加或减少。
J Immunol. 1991 Sep 15;147(6):1786-91.
4
Nature of the ligand recognized by a hapten- and carrier-specific, MHC-restricted T cell receptor.一种半抗原和载体特异性、MHC限制的T细胞受体所识别的配体的性质。
J Immunol. 1993 May 1;150(9):3806-16.
5
Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells.特定的蛋白水解切割限制了活细胞中可供MHC I类分子使用的肽库的多样性。
J Immunol. 1999 Apr 15;162(8):4712-9.
6
Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.对卵清蛋白的体内主要反应。探究Kb结合基序的预测价值。
J Immunol. 1993 Feb 15;150(4):1212-22.
7
Polymorphism in the beta chain of IAq versus IAp influences presentation of protein but not peptide antigens.IAq与IAp的β链多态性影响蛋白质而非肽抗原的呈递。
Cell Immunol. 1995 Oct 15;165(2):202-10. doi: 10.1006/cimm.1995.1206.
8
A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.一种在抗原呈递方面存在缺陷的突变抗原呈递细胞表达构象改变的II类主要组织相容性复合体分子。
J Immunol. 1993 May 15;150(10):4206-17.
9
Relationship between T cell receptors and antigen-binding factors. I. Specificity of functional T cell receptors on mouse T cell hybridomas that produce antigen-binding T cell factors.T细胞受体与抗原结合因子之间的关系。I. 产生抗原结合性T细胞因子的小鼠T细胞杂交瘤上功能性T细胞受体的特异性。
J Immunol. 1989 Dec 15;143(12):3909-16.
10
Fine specificity of murine class II-restricted T cell clones for synthetic peptides of influenza virus hemagglutinin. Heterogeneity of antigen interaction with the T cell and the Ia molecule.小鼠II类分子限制性T细胞克隆对流感病毒血凝素合成肽的精细特异性。抗原与T细胞及Ia分子相互作用的异质性。
J Immunol. 1988 Jun 15;140(12):4083-90.

引用本文的文献

1
Acute-phase response and its biomarkers in acute and chronic urticaria.急性和慢性荨麻疹中的急性期反应及其生物标志物
Postepy Dermatol Alergol. 2018 Aug;35(4):400-407. doi: 10.5114/ada.2018.77672. Epub 2018 Aug 21.
2
Ana o 1 and Ana o 2 cashew allergens share cross-reactive CD4(+) T cell epitopes with other tree nuts.Ana o 1和Ana o 2腰果过敏原与其他坚果共享交叉反应性CD4(+) T细胞表位。
Clin Exp Allergy. 2016 Jun;46(6):871-83. doi: 10.1111/cea.12746.
3
Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation.
候选类风湿关节炎自身抗原聚集蛋白聚糖由抗原特异性 B 细胞呈递可诱导增强的 CD4(+) T 辅助型 1 亚群分化。
Immunology. 2012 Apr;135(4):344-54. doi: 10.1111/j.1365-2567.2011.03548.x.
4
Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome.用树突状细胞系衍生的内溶酶体降解组评估蛋白质免疫原性。
PLoS One. 2011 Feb 16;6(2):e17278. doi: 10.1371/journal.pone.0017278.
5
Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis.可溶性甘露糖基化髓鞘肽在实验性自身免疫性脑脊髓炎期间抑制自身反应性T细胞的致脑炎作用。
Am J Pathol. 2007 Jan;170(1):272-80. doi: 10.2353/ajpath.2007.060335.
6
Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy.HER-2/neu癌蛋白的免疫生物学及其在癌症免疫治疗中的潜在应用。
Cancer Immunol Immunother. 2004 Mar;53(3):166-75. doi: 10.1007/s00262-003-0475-7. Epub 2003 Dec 18.
7
Proteolysis and antigen presentation by MHC class II molecules.蛋白酶解作用与MHC II类分子的抗原呈递
Adv Immunol. 2002;80:71-114. doi: 10.1016/s0065-2776(02)80013-x.
8
Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes.吞噬细胞使化学物质具有免疫原性:单核吞噬细胞将金(I)氧化为能致敏T细胞的金(III)代谢产物。
Arch Toxicol. 1995;69(7):450-9. doi: 10.1007/s002040050198.
9
Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing.甲醛处理蛋白质可通过限制抗原加工来抑制向T细胞的呈递。
Infect Immun. 1994 May;62(5):1830-4. doi: 10.1128/iai.62.5.1830-1834.1994.